Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    CVM

Delayed Quote. Delayed  - 07/25 09:59:48 pm
0.475 USD   +4.40%
07/11 CEL SCI : NEW STORY CEL-SCI Granted European Patent for Multikine Ca..
07/11 CEL SCI : Granted European Patent for Multikine Cancer Immunotherapy..
07/05 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in Ju..
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

CEL SCI CORP : Submission of Matters to a Vote of Security Holders (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/22/2016 | 10:14pm CEST

Item 5.07. Submission of Matters to a Vote of Securities Holders.


      The annual meeting of CEL-SCI's shareholders was held on July 22, 2016. At
the meeting the following persons were elected as directors for the upcoming
year:

                                    Votes
                        ------------------------------             Broker
 Name                          For         Against                Non-Votes
------                         ---         -------                ---------

 Maximilian de Clara        30,789,923    2,360,698              63,754,716
 Geert R. Kersten           31,385,941    1,764,680              63,754,716
 Alexander G. Esterhazy     27,520,093    5,630,528              63,754,716
  Peter R. Young            27,488,711    5,661,910              63,754,716
 Bruno Baillavoine          28,851,002    4,299,619              63,754,716

      At the meeting the following were ratified by CEL-SCI's shareholders:

(2) the adoption of CEL-SCI's 2016 Incentive Stock Option Plan which

provides that up to 1,500,000 shares of common stock may be issued

upon the exercise of options granted pursuant to the Incentive Stock

Option Plan;

(3) the adoption of CEL-SCI's 2016 Non-Qualified Stock Option Plan which

provides that up to 2,000,000 shares of common stock may be issued

upon the exercise of options granted pursuant to the Non-Qualified

Stock Option Plan;

(4) the adoption of CEL-SCI's 2016 Stock Bonus Plan which provides that up

to 2,000,000 shares of common stock may be issued to persons granted

stock bonuses pursuant to the Stock Bonus Plan;

(5) the appointment of BDO USA, LLP as CEL-SCI's independent registered

public accounting firm for the fiscal year ending September 30, 2016;


      The following is a tabulation of votes cast with respect to proposals 2,
3, 4 and 5:

                                Votes
                 -------------------------------------          Broker
 Proposal           For           Against       Abstain        Non-Votes
 --------           ---           -------       -------        ----------

   (2)          23,391,894      9,434,136      324,591        63,754,716
   (3)          22,976,764      9,843,306      330,551        63,754,716
   (4)          27,294,559      5,509,577      346,485        63,754,716
   (5)          89,155,183      5,187,493    2,562,661                 0


                                       2

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CEL-SCI CORPORATION
07/22 CEL SCI CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
07/11 CEL SCI : NEW STORY CEL-SCI Granted European Patent for Multikine Cancer Immunot..
07/11 CEL SCI : Granted European Patent for Multikine Cancer Immunotherapy in Combinat..
07/05 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in June for Its P..
07/05 CEL SCI : Reports Monthly Patient Enrollment in June for Its Phase 3 Head and Ne..
06/09 CEL SCI : to Present at the Fifth Annual Marcum MicroCap Conference
06/07 CEL SCI : NEW STORY CEL-SCI to Present at LD Micro Invitational
06/07 CEL SCI : to Present at LD Micro Invitational
06/02 CEL SCI : Announces the Closing of Its $5 Million Registered Direct Offering
06/01 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in May for Its Ph..
More news
Sector news : Bio Therapeutic Drugs
12:45a GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/18 CEL-SCI inks $5M capital raise via private placement; shares off 4% premarket
05/10 Cel-Sci reports FQ2 results
04/13 CEL-SCI's Manufacturing Of Cancer-Killer Multikine Marks A World-Class Facili..
02/22 A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016
02/09 Cel-Sci reports FQ1 results
Advertisement
Chart CEL-SCI CORPORATION
Duration : Period :
CEL-SCI Corporation Technical Analysis Chart | CVM | US1508375086 | 4-Traders
Full-screen chart
Managers
NameTitle
Geert R. Kersten CEO, CFO, Treasurer, Director & CAO
Maximilian de Clara President & Director
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION22.97%64
AMGEN, INC.2.61%125 123
GILEAD SCIENCES, INC.-12.49%117 933
CELGENE CORPORATION-9.88%83 603
REGENERON PHARMACEUTIC..-27.26%41 496
VERTEX PHARMACEUTICALS..-23.89%23 689
More Results